These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35960302)

  • 1. The default of 1998 and pharmaceutical market. Report I. The chronicle of disaster.
    Zatravkin SN; Ignatiev VG; Vishlenkova EA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Jul; 30(4):683-691. PubMed ID: 35960302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The 1998 default and the pharmaceutical market. Report 2: Predictions and Estimates].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Sep; 30(5):903-908. PubMed ID: 36282666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Russian pharmaceutical industry in 1990s. Report III. Insider vision].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 May; 30(3):503-507. PubMed ID: 35670410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Renaissance of Russian pharmaceutical market (2000-2004). Report III. The interests of consumers].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Mar; 31(2):290-296. PubMed ID: 37129405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Renaissance of Russian pharmaceutical market (2000-2004). Report I. The field players].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Dec; 30(6):1358-1366. PubMed ID: 36541323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Renaissance of Russian pharmaceutical market (2000-2004). Report II. The Pharma servants of Russia].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):112-119. PubMed ID: 36801885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossing the fourth hurdle.
    Rawlins MD
    Br J Clin Pharmacol; 2012 Jun; 73(6):855-60. PubMed ID: 22404227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Russian pharmaceutical branch in 1990s. Report 1. From the Soviet to the market].
    Zatravkin SN; Vishlenkova EA; Ignatiev VG
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Jan; 30(1):160-166. PubMed ID: 35157399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost benefit of investment on quality in pharmaceutical manufacturing: WHO GMP pre- and post-certification of a Nigerian pharmaceutical manufacturer.
    Anyakora C; Ekwunife O; Alozie F; Esuga M; Ukwuru J; Onya S; Nwokike J
    BMC Health Serv Res; 2017 Sep; 17(1):665. PubMed ID: 28923044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market watch: Top drugs and companies by sales in 2017.
    Urquhart L
    Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical industry financial performance.
    Goodman M
    Nat Rev Drug Discov; 2009 Dec; 8(12):927-8. PubMed ID: 19949398
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 18. The acceptable face of international competition. Stereophobia: an economic afterthought.
    Ariëns EJ
    Trends Pharmacol Sci; 1988 Sep; 9(9):317. PubMed ID: 3270968
    [No Abstract]   [Full Text] [Related]  

  • 19. [Healthy pharmaceutical policy].
    González Pier E
    Salud Publica Mex; 2008; 50 Suppl 4():S488-95. PubMed ID: 19082260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.